The global companion animal vaccine market size was valued at USD 3.82 billion in 2025 and is projected to grow from USD 4.06 billion in 2026 to USD 6.59 billion by 2034, registering a CAGR of 6.24% during the forecast period (2026-2034). North America dominated the companion animal vaccine market with a share of 39.86% in 2025.
Companion animal vaccines are biological products designed to stimulate the immune system of pets, primarily dogs and cats, to protect them against infectious diseases caused by viruses, bacteria, and other pathogens. They are generally tracked under HSN Code 3002 (immunological products and vaccines), specifically HSN 3002 42 00 for vaccines for veterinary medicine in India, and SIC Code 2836 (biological products, except diagnostic substances).
The companion animal vaccine market demand is driven by high pet ownership, a focus on preventive veterinary healthcare, and expenditure on pet health and wellness. Veterinary clinics, animal hospitals, and pharmaceutical companies are introducing advanced vaccines, contributing to companion animal vaccine market growth.
Download a Free Sample To learn more about this report,
Evolution of Combination Vaccines
The companion animal vaccine market analysis shows that veterinary pharmaceutical companies are developing combination vaccines for dogs and cats. This encourages manufacturers to combine protection against multiple infectious diseases into a single formulation. For example, Merck Animal Health’s Nobivac Canine 1-DAPPv combines protection against canine distemper, adenovirus, parainfluenza, and parvovirus, reflecting the evolving format of canine vaccines and infectious disease prevention.
Advancements in Vaccine Adjuvant Technologies
Advancements in vaccine formulation technologies such as specialized adjuvant systems and adjuvant-free formulations encourage medicine manufacturers to explore different approaches to immune stimulation, antigen delivery, and vaccine tolerability, particularly in feline vaccines. For example, Boehringer Ingelheim’s PUREVAX range includes adjuvant-free cat vaccines and recombinant canarypox-based products.
Supply chain disruptions are expected to have a moderate impact on the companion animal vaccine market share due to its direct exposure to shortages of vaccine antigens, biological raw materials, and cold chain transportation services. A capacity-constrained recovery is likely, as limited access to biological ingredients, specialized manufacturing capacity, and temperature-controlled distribution can delay vaccine production. Supply chain constraints could reduce the growth from 6.24% to 4.74%, a decline of 1.50 percentage points. As supply conditions normalize, the companion animal vaccine market growth is expected to gradually return to 6.24%.
The companion animal vaccine market forecasts investments to develop new vaccine technologies. In June 2026, Elanco Animal Health announced a USD 25 million multi-year commitment to establish Elanco Ventures, a corporate venture capital platform investing in early-stage animal-health therapeutics and supporting technologies.
Demand for Preventive Veterinary Care and Adoption of Routine Vaccination Drive Market
Pet owners' focus on preventive veterinary care is strengthening demand for companion animal vaccines across veterinary clinics, animal hospitals, and pet healthcare centers. Pet owners increasingly prioritize routine immunization to reduce the risk of infectious diseases and support long-term animal health. Thus, veterinary service providers encourage regular vaccination through wellness visits, booster schedules, and preventive healthcare programs.
Routine vaccination supports demand for vaccines against common canine and feline diseases. Core immunization programs include protection against canine distemper, parvovirus, rabies, and feline panleukopenia.
Affordability Issues and Temperature-Sensitive Nature of Vaccines Restrict Adoption
Companion animal vaccines and veterinary administration services create a financial burden for price-sensitive pet owners. These expenses lead households to delay vaccinations or skip recommended doses, reducing adoption of dog vaccines, cat vaccines, and other preventive veterinary care products.
Temperature-sensitive nature of companion animal vaccines requires controlled storage and transportation, with many products needing refrigeration between 2°C and 8°C. Inadequate refrigeration, power interruptions, and temperature fluctuations reduce vaccine potency, increase wastage, and raise distribution costs.
Integration of Pet Insurance and Veterinary Partnerships Offers Growth Opportunities to Market Players
Pet insurance integration offers growth opportunities for companion animal vaccine manufacturers and veterinary service providers through insurance-linked preventive care plans. Partnerships with pet insurers expand access to vaccination coverage, encourage routine animal immunization, and create recurring revenue through bundled pet healthcare services.
Veterinary partnerships create opportunities for vaccine manufacturers by expanding distribution through animal hospitals, independent clinics, shelters, and veterinary networks. These collaborations improve access in underserved regions and generate additional revenue through institutional supply agreements and long-term procurement partnerships.
Attenuated live vaccines dominated the vaccine type segment with a share of 35.8% in 2025, supported by their widespread use in routine immunization programs and their ability to provide protection against infectious diseases in companion animals. Continued adoption for preventing common canine and feline diseases supports demand for attenuated live vaccines across veterinary clinics and animal healthcare facilities.
DNA vaccines are likely to grow at a CAGR of 7.38% during the forecast period, driven by advancements in genetic vaccine technology, increasing research into innovative immunization solutions, and the need for effective protection against companion animal diseases.
Request Customizationto receive a tailored report.
In 2025, canines led the animal type segment with a share of 58.7%, owing to the widespread adoption of routine vaccination and strong demand for preventive healthcare among dog owners. Veterinary clinics and animal hospitals continue to provide immunization against rabies, canine distemper, and parvovirus, supporting sustained demand for canine vaccines.
Feline segment is projected to grow at a CAGR of 6.47% during the forecast period, fueled by increasing cat ownership, rising awareness of preventive veterinary care, and growing demand for feline vaccines to protect against infectious diseases.
Veterinary hospitals and clinics had a share of 64.5% in 2025. They continue to provide vaccinations against common canine and feline diseases, supporting sustained demand for companion animal vaccines across preventive veterinary care settings.
E-commerce segment will expand to 8.14% CAGR from 2026 to 2034, propelled by digital access to pet healthcare products, the convenience of online ordering, and the expansion of veterinary and pet pharmacy platforms.
Speak to an Analystto discuss market opportunities.
The North America companion animal vaccine market accounted for a dominant share of 39.86% in 2025.
USDA’s Animal and Plant Health Inspection Service (APHIS) requires veterinary biologics, including companion animal vaccines, to meet standards for safety, purity, potency, and efficacy before commercial distribution. These requirements push manufacturers to develop recombinant vaccines, improve formulations, and innovate vaccines targeting canine and feline infectious diseases.
According to Agriculture and Agri-Food Canada, approximately 12.2 million Canadian households owned dogs and/or cats, reflecting a substantial base of companion animals requiring routine vaccination and veterinary healthcare. Thus, awareness of infectious disease prevention in dogs and cats drives the Canadian market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific companion animal vaccine market will reach 7.68% CAGR, showcasing the fastest-growing regional market.
Japan’s Ministry of Agriculture, Forestry and Fisheries established an Animal Vaccine Strategy to strengthen vaccine development, approval, manufacturing and sales. These initiatives support vaccine innovation for companion animals, including improved formulations targeting canine and feline infectious diseases.
The Chinese market is supported by rising pet ownership, increasing expenditure on veterinary healthcare, and growing awareness of preventive vaccination among pet owners. Investments in veterinary healthcare infrastructure and the expansion of animal health services continue to strengthen the country's veterinary pharmaceuticals industry.
Indian Council of Agricultural Research’s Indian Veterinary Research Institute (IVRI) has developed an indigenous live-attenuated canine parvovirus vaccine candidate based on a strain relevant to infections circulating among India’s dog population. This development boosts commercialization of locally developed formulations and expand preventive healthcare options for pet dogs, veterinary clinics and animal shelters.
Europe's companion animal vaccine market is anticipated to grow at a CAGR of 5.94% during the forecast period.
UK Veterinary Medicines Directorate published a Statement of Intent on UK Veterinary Vaccine Availability, identifying supply shortages and gaps in the development of new vaccines and outlining plans for a five-year, cross-sector action plan. UK manufacturers are developing vaccines for canine and feline infectious diseases, strengthen supply reliability and introduce innovative formulations to address unmet veterinary needs.
The Germany companion animal vaccine market was valued at approximately USD 300 million in 2025, supported by established veterinary healthcare infrastructure, high awareness of preventive animal healthcare, and strong demand for vaccination against infectious diseases. Germany’s developed veterinary services sector and emphasis on routine animal immunization support demand for dog vaccines, cat vaccines, and rabies vaccines.
The Latin America companion animal vaccine market is expected to grow at a CAGR of 6.51% during the forecast period. Brazil benefits from an established animal health industry and demand for dog vaccines and rabies vaccines. In Mexico, expanding veterinary services and greater attention to preventive pet healthcare support demand for companion animal vaccines, including feline vaccines and canine vaccines.
The Middle East & Africa companion animal vaccine market is expected to grow at a CAGR of 6.37% during the forecast period. UAE Ministry of Climate Change and Environment specifies vaccines for rabies and other infectious diseases in dogs and cats, including canine parvovirus, distemper, feline panleukopenia and feline calicivirus. In South Africa, established animal health services and continued demand for rabies vaccines support companion animal immunization and market development.
The companion animal vaccine market competitive landscape highly is competitive, with established animal health pharmaceutical companies and veterinary vaccine developers. Key players such asZoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, and Ceva Santé Animale are estimated to account for 50–60% of the global companion animal vaccine market share.
Established players compete mainly through vaccine efficacy, safety, disease coverage, product innovation, and veterinary distribution networks. Other regional players focus on vaccines for specific animal diseases, locally prevalent infections, and cost-effective products for dogs, cats, and other companion animals.
November 2025: Zoetis launched Vanguard Recombishield Injectable in the United States, a canine vaccine against Bordetella bronchiseptica, which causes kennel cough.
March 2026: Merck Animal Health received Canadian approval for NOBIVAC NXT 3-Rabies, an RNA-particle-based vaccine designed to protect dogs and cats against rabies.
June 2026: Elanco Animal Health received U.S. Department of Agriculture approval for TruCan Ultra Lyme-L4, a combination vaccine protecting dogs against Lyme disease and leptospirosis.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Animal Sedative Market Size, Forecast, Demand, Opportunities, 2034
Animal Wound Care Market Size, Forecast, Opportunities, 2034
Companion Animal Healthcare Market Size, Share, 2034
Animal Microchip Implant Market Size, Share, Growth, 2034
Pet Care Market Size, Share, Growth, Analysis, Report, 2034
Veterinary Pharmaceutical Drugs Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com